|
|
 |
Dr. John Dick’s longstanding research interests have focused on stem cells and cancer, including the development of an important model using an immune deficient mice (NOD/SCID), to study both normal and leukemic stem cells. Studies indicate that cancer stem cells initiate many types of cancer, including leukemia, skin, colon, breast and brain cancers. Dr. Dick’s research is aimed at characterizing cancer stem cells in leukemia, identifying markers for these cells, and understanding the pathways involved in their development.
Dr. Dick is also identifying markers for cancer stem cells in a collaborative effort to develop a new diagnostic instrument and related reagents for the identification of cancer based on the determination of these rare cells. This novel tool would provide both diagnostic and prognostic information for the identification and treatment of cancers and ultimately many diseases.
|
|
Researcher Information
Senior Scientist
Division of Cellular & Molecular Biology
Suite 8-355, Toronto Medical Discovery Tower
101 College Street
Toronto, Ontario
Canada M5G 1L7
|
|
|
Dr. Dick is Senior Scientist, Division of Cellular & Molecular Biology at Toronto General Research Institute, University Health Network and also Professor, Medical Genetics and Microbiology at The University of Toronto. He holds a Canada Research Chair in Stem Cell Biology. Dr. Dick received a PhD in Microbiology and Biochemistry from the University of Manitoba in 1984. He has received numerous honours and awards including The Robert L. Noble Prize, Academic from the National Cancer Institute of Canada, The Wellcome Trust Travel Award from the Wellcome Group, UK and The Michael Smith Award of Excellence Prize, Academic from the Medical Research Council of Canada
|
|
Researcher Information
Senior Scientist
Division of Cellular & Molecular Biology
Suite 8-355, Toronto Medical Discovery Tower
101 College Street
Toronto, Ontario
Canada M5G 1L7
|
|
|
|
Chiu PP, Jiang H, Dick JE. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood. 2010
|
|
|
Milyavsky M, Gan OI, Trottier M, Komosa M, Tabach O, Notta F, Lechman E, Hermans KG, Eppert K, Konovalova Z, Ornatsky O, Domany E, Meyn MS, Dick JE. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell. 2010 Aug 6;7(2):186-97.
|
|
|
Kennedy JA, Barabe F, Patterson BJ, Bayani J, Squire JA, Barber DL, Dick JE. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci USA. 2006,103(45):16930-5.
|
|
|
McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010 Jul 15;116(2):193-200.
|
|
|
Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, Dick JE. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev. 2009 Sep 1;23(17):2076-87.
|
|
|
Researcher Information
Senior Scientist
Division of Cellular & Molecular Biology
Suite 8-355, Toronto Medical Discovery Tower
101 College Street
Toronto, Ontario
Canada M5G 1L7
|
|
|
|
|
Leukemia stem cells (LSCs) are a biologically distinct blast population positioned at the apex of the acute myeloid leukemia (AML) developmental hierarchy. A more complete understanding of the unique properties of LSCs is crucial for the identification of novel AML regulatory pathways and the subsequent development of innovative therapies that effectively target these cells in leukemia patients. UHN researchers have identified a microRNA (miR-126) that has utility in monitoring the purification of acute myeloid leukemia (AML) stem cells.
send a message
more
Leukemia stem cells (LSCs) are a biologically distinct blast population positioned at the apex of the acute myeloid leukemia (AML) developmental hierarchy. A more complete understanding of the unique properties of LSCs is crucial for the identification of novel AML regulatory pathways and the subsequent development of innovative therapies that effectively target these cells in leukemia patients.
UHN researchers have identified a microRNA (miR-126) that has utility in monitoring the purification of acute myeloid leukemia (AML) stem cells. Similarly, it could be useful in the purification of normal hematopoietic stem cells. Stem cell enrichment has the potential to enhance the therapeutic use of bone marrow transplantation. Thus, miR-126 expression profiling could also be used in the diagnosis and treatment of AML by providing a novel biomarker for screening the bone marrow and peripheral blood of leukemia patients.
send a message
less
|
|
|
|
ORGANIZATIONS
PROJECTS
RESOURCES
There are no related resources for this profile.
ATTACHMENTS
There are no downloads available for this profile.
OTHER INFORMATION
There is no other information available for this profile.
|
|
|
|
|
|
YOU MAY ALSO BE INTERESTED IN:
CATEGORIES
Disciplinary Focus
Experimental biology and chemistry
Research Paradigm
Focused-scope projects,
Large-scale projects,
Technology development
Core Technology
Cells and tissues:
Cell imaging
Nucleic acids:
DNA sequencing,
Gene expression systems,
Genotyping,
Microarrays
Proteins:
Mass spectrometry
Sign-up to edit this profile
|
